Stock DNA GENENTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Genentech, Inc.

Equities

DNA

US3687104063

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Genentech, Inc.
2015 Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015 CI
2009 GENENTECH : Roche buys Genentech for $46.8 billion RE

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
Genentech, Inc. : Dalradian Appoints Chief Operating Officer
PU
GENENTECH : Roche Completes Acquisition of Genentech
PR
GENENTECH : Roche Completes Tender Offer for Genentech
PR
GENENTECH : Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
PR
GENENTECH : Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
PR
GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
PR
Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer
BU
Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox
BU
Genentech : Genentech Announces Second Quarter 2007 Results
BU
Genentech : Genentech Announces July 11 Webcast Discussion of Earnings and Other Business Results
BU
Genentech : Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
BU
Genentech : Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
BU
Genentech : Phase III Study Shows Avastin Plus Interferon Therapy Nearly Doubled Median Progression-Free Survival in Patients With Previously Untreated Advanced Kidney Cancer
BU
Genentech : Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
BU
Genentech : Genentech Announces June 4 Webcast Discussion of Data Presented at ASCO
BU
Genentech : Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
BU
Genentech : Genentech Extends Stock Repurchase Program
BU
Genentech : Genentech Announces First Quarter 2007 Results
BU
Genentech : Genentech to Provide Business Update at Annual Investment Community Meeting
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNA Stock
  4. News Genentech, Inc.
  5. Press Releases